Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus CYLERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus CYLERT.
ADZENYS ER vs CYLERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
CNS stimulant; increases extracellular dopamine and norepinephrine levels by blocking their reuptake and enhancing release.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
37.5 mg orally once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Terminal elimination half-life is 12-30 hours in children (mean 19 hours) and 8-14 hours in adults; the long half-life supports once-daily dosing, but accumulation can occur with repeated dosing
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Primarily renal (80-90% as unchanged drug and metabolites, with 50-60% as unchanged pemoline), minor biliary/fecal elimination (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant